Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Dec 10

PMID 34884550

Citations 13

Authors

Mariana Segovia-Mendoza

Janice Garcia-Quiroz

Lorenza Diaz

Rocio Garcia-Becerra

Affiliations

Soon will be listed here.

Abstract

Preclinical, clinical, and epidemiological studies indicate that vitamin D3 (VD) deficiency is a risk factor for the development of breast cancer. Underlying mechanisms include the ability of calcitriol to induce cell differentiation, inhibit oncogenes expression, and modify different signaling pathways involved in the control of cell proliferation. In addition, calcitriol combined with different kinds of antineoplastic drugs has been demonstrated to enhance their beneficial effects in an additive or synergistic fashion. However, a recognized adjuvant regimen based on calcitriol for treating patients with breast cancer has not yet been fully established. Accordingly, in the present work, we review and discuss the preclinical and clinical studies about the combination of calcitriol with different oncological drugs, aiming to emphasize its main therapeutic benefits and opportunities for the treatment of this pathology.

Citing Articles

Targeting Surface Markers in Anaplastic Thyroid Cancer: Future Directions in Ligand-bound Therapy.

Pakkianathan J, Chan S, Cruz J, Ewan K, Simental A, Khan S J Endocr Soc. 2025; 9(4):bvaf035.

PMID: 40071065 PMC: 11893542. DOI: 10.1210/jendso/bvaf035.

Pretreatment plasma vitamin D and response to neoadjuvant chemotherapy in breast cancer: evidence from pooled analysis of cohort studies.

Shu C, Yang Q, Huang J, Xie X, Li H, Wu H Int J Surg. 2025; 110(12):8126-8135.

PMID: 39806750 PMC: 11634150. DOI: 10.1097/JS9.0000000000002142.

Unveiling the Link Between Breast Cancer Treatment and Osteoporosis: Implications for Anticancer Therapy and Bone Health.

Goel B, Virmani T, Jain V, Kumar G, Sharma A, Al Noman A Biomed Res Int. 2024; 2024:5594542.

PMID: 39574432 PMC: 11581800. DOI: 10.1155/2024/5594542.

Investigating the Mechanisms of Anti-tumoral Effect of Combination Therapy of Calcitriol and Sodium Pentaborate Pentahydrate on HepG2 Hepatocellular Carcinoma Cells.

Degirmenci N, Padar G, Sahin F, Omeroglu Ulu Z Biol Trace Elem Res. 2024; .

PMID: 39441231 DOI: 10.1007/s12011-024-04416-w.

The therapeutic potential of 1, 25-dihydroxy vitamin D3 on cisplatin-affected neurological functions is associated with the regulation of oxidative stress and inflammatory markers as well as levels of MMP2/9.

Niapour A, Abdollahzadeh M, Ghaheri Fard S, Saadati H Metab Brain Dis. 2024; 39(6):1189-1200.

PMID: 39017968 DOI: 10.1007/s11011-024-01382-z.

References

Gerstmeier J, Possmayer A, Bozkurt S, Hoffmann M, Dikic I, Herold-Mende C . Calcitriol Promotes Differentiation of Glioma Stem-Like Cells and Increases Their Susceptibility to Temozolomide. Cancers (Basel). 2021; 13(14). PMC: 8303292. DOI: 10.3390/cancers13143577. View

Ortega M, Fraile-Martinez O, Asunsolo A, Bujan J, Garcia-Honduvilla N, Coca S . Signal Transduction Pathways in Breast Cancer: The Important Role of PI3K/Akt/mTOR. J Oncol. 2020; 2020:9258396. PMC: 7085392. DOI: 10.1155/2020/9258396. View

Lundqvist J, Yde C, Lykkesfeldt A . 1α,25-dihydroxyvitamin D3 inhibits cell growth and NFκB signaling in tamoxifen-resistant breast cancer cells. Steroids. 2014; 85:30-5. DOI: 10.1016/j.steroids.2014.04.001. View

Fan P, Fan S, Wang H, Mao J, Shi Y, Ibrahim M . Genistein decreases the breast cancer stem-like cell population through Hedgehog pathway. Stem Cell Res Ther. 2013; 4(6):146. PMC: 4054948. DOI: 10.1186/scrt357. View

Wilhelm C, Clor Z, Kelts J . Effect of Vitamin D on Paclitaxel Efficacy in Triple-negative Breast Cancer Cell Lines. Anticancer Res. 2018; 38(9):5043-5048. DOI: 10.21873/anticanres.12823. View

Reinbolt R, Mangini N, Hill J, Levine L, Dempsey J, Singaravelu J . Endocrine therapy in breast cancer: the neoadjuvant, adjuvant, and metastatic approach. Semin Oncol Nurs. 2015; 31(2):146-55. DOI: 10.1016/j.soncn.2015.02.002. View

Garcia-Quiroz J, Garcia-Becerra R, Barrera D, Santos N, Avila E, Ordaz-Rosado D . Astemizole synergizes calcitriol antiproliferative activity by inhibiting CYP24A1 and upregulating VDR: a novel approach for breast cancer therapy. PLoS One. 2012; 7(9):e45063. PMC: 3440370. DOI: 10.1371/journal.pone.0045063. View

Koga M, Sutherland R . Retinoic acid acts synergistically with 1,25-dihydroxyvitamin D3 or antioestrogen to inhibit T-47D human breast cancer cell proliferation. J Steroid Biochem Mol Biol. 1991; 39(4A):455-60. DOI: 10.1016/0960-0760(91)90238-z. View

Friedrich M, Reichert K, Woeste A, Polack S, Fischer D, Hoellen F . Effects of Combined Treatment with Vitamin D and COX2 Inhibitors on Breast Cancer Cell Lines. Anticancer Res. 2018; 38(2):1201-1207. DOI: 10.21873/anticanres.12340. View

10.

Proietti S, Cucina A, Dobrowolny G, Danselmi F, Dinicola S, Masiello M . Melatonin down-regulates MDM2 gene expression and enhances p53 acetylation in MCF-7 cells. J Pineal Res. 2014; 57(1):120-9. DOI: 10.1111/jpi.12150. View

11.

Majumdar A, Banerjee S, Nautiyal J, Patel B, Patel V, Du J . Curcumin synergizes with resveratrol to inhibit colon cancer. Nutr Cancer. 2009; 61(4):544-53. PMC: 6370344. DOI: 10.1080/01635580902752262. View

12.

Larsen S, Heiberg I, Lykkesfeldt A . Anti-oestrogen resistant human breast cancer cell lines are more sensitive towards treatment with the vitamin D analogue EB1089 than parent MCF-7 cells. Br J Cancer. 2001; 84(5):686-90. PMC: 2363804. DOI: 10.1054/bjoc.2000.1646. View

13.

Santos-Martinez N, Diaz L, Ortiz-Ortega V, Ordaz-Rosado D, Prado-Garcia H, Avila E . Calcitriol induces estrogen receptor α expression through direct transcriptional regulation and epigenetic modifications in estrogen receptor-negative breast cancer cells. Am J Cancer Res. 2022; 11(12):5951-5964. PMC: 8727803. View

14.

Li Y, Seto E . HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb Perspect Med. 2016; 6(10). PMC: 5046688. DOI: 10.1101/cshperspect.a026831. View

15.

Yoon S, Bae K, Cho Y, Han S, Kim H, Lim H . Disease Progression Modeling Analysis of the Change of Bone Mineral Density by Postoperative Hormone Therapies in Postmenopausal Patients With Early Breast Cancer. J Clin Pharmacol. 2019; 59(11):1543-1550. DOI: 10.1002/jcph.1451. View

16.

Chen J, Tang Z, Slominski A, Li W, Zmijewski M, Liu Y . Vitamin D and its analogs as anticancer and anti-inflammatory agents. Eur J Med Chem. 2020; 207:112738. DOI: 10.1016/j.ejmech.2020.112738. View

17.

Wang Q, Lee D, Sysounthone V, Chandraratna RAS , Christakos S, Korah R . 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat. 2001; 67(2):157-68. DOI: 10.1023/a:1010643323268. View

18.

Thill M, Reichert K, Woeste A, Polack S, Fischer D, Hoellen F . Combined treatment of breast cancer cell lines with vitamin D and COX-2 inhibitors. Anticancer Res. 2015; 35(2):1189-95. View

19.

Koshizuka K, Koike M, Kubota T, Said J, Binderup L, Koeffler H . Novel vitamin D3 analog (CB1093) when combined with paclitaxel and cisplatin inhibit growth of MCF-7 human breast cancer cells in vivo. Int J Oncol. 1998; 13(3):421-8. DOI: 10.3892/ijo.13.3.421. View

20.

Matthews D, LaPorta E, Zinser G, Narvaez C, Welsh J . Genomic vitamin D signaling in breast cancer: Insights from animal models and human cells. J Steroid Biochem Mol Biol. 2010; 121(1-2):362-7. PMC: 2906670. DOI: 10.1016/j.jsbmb.2010.03.061. View